One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis and is at the forefront of research into new medicines for neurological conditions and rare genetic disorders. Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options.

Type
Public
HQ
Cambridge, US
Founded
1978
Size (employees)
7,400 (est)
Biogen was founded in 1978 and is headquartered in Cambridge, US

Key People at Biogen

Michel Vounatsos

Michel Vounatsos

CEO

Biogen Office Locations

Biogen has office in Cambridge
Cambridge, US

Biogen Metrics

Biogen Summary

Market capitalization

$61.6 B

Closing share price

$285
Biogen's current market capitalization is $61.6 B.

Biogen Market Value History

Market Position – drug development, scientific research, biotech, clinical research, Health

Biogen Online Presence

Biogen News

Biogen Company Life

You may also be interested in